COMMUNIQUÉS West-GlobeNewswire

Mentions légales

* Temps de fermeture de l’ulcère avec HydroTac® : moins de 15 semaines alors que les données de la littérature montrent que 40-60% des ulcères nécessitent 20 à 24 semaines pour cicatriser. (1) Mikosiński, J. et al. Clinical assessment of a foam dressing containing growth factor-enhancing hydrated polyurethanes. J Wound Care.2018;27(9):608-18. HydroTac® : DM de classe IIb – Fabricant : PAUL HARTMANN AG – Organisme notifié : CE 0123. Lire attentivement les instructions figurant dans la notice (et/ou sur l’étiquetage). Remboursé par les organismes d’assurance maladie : consultez les modalités sur le site www.ameli.fr. Réf : 14122018. Date de création : Décembre 2018

resTORbio, Inc. Announces Closing Public Offering of Common Stock
22/03/2019 - 15:02
BOSTON, March 22, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (“resTORbio” or the “Company”) (Nasdaq:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to [...]
Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology
22/03/2019 - 15:19
NORCROSS, Ga., March 22, 2019 (GLOBE NEWSWIRE) -- Providence Cancer Institute and Galectin Therapeutics Inc. (NASDAQ: GALT) , the leading developer of therapeutics that target galectin proteins, announced today a [...]
The observation status of Oncology Venture is removed
22/03/2019 - 15:43
Press release Hørsholm, Denmark and Cambridge, MA, US, March 22, 2019 – Oncology Venture A/S announced today that the observation status for the share on Nasdaq First North has been removed. The decision was taken by [...]
Assure Holdings Announces Estimated Impact from Fourth Quarter 2018 Increase in Bad Debt Expense
22/03/2019 - 16:13
DENVER, March 22, 2019 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “ Company ” or “ Assure ”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services, announced today that it was increasing [...]
Correction to Financial Statement Bulletin of BBS-Bioactive Bone Substitutes Plc, published 22th March 2019 at 9:00 CET
22/03/2019 - 17:00
BBS-Bioactive Bone Substitutes Plc Correction to Financial Statement Bulletin of BBS-Bioactive Bone Substitutes Plc, published 22th March 2019 at 9:00 CET. Unfortunately, some incorrect dates and periods were in the [...]
2018 Annual Report and Accounts and Notice of AGM
22/03/2019 - 17:00
LONDON, March 22, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]
Correction: Removal of the MAR plate in the release: The observation status of Oncology Venture is removed
22/03/2019 - 17:24
Press release Hørsholm, Denmark and Cambridge, MA, US, March 22, 2019 – Oncology Venture A/S announced today that the observation status for the share on Nasdaq First North has been removed. The decision was taken by [...]
Genmab Announces European Regulatory Submission for Daratumumab in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma
22/03/2019 - 11:48
Company Announcement Type II variation application submitted to the EMA for daratumumab in combination with lenalidomide and dexamethasone as treatment for newly diagnosed multiple myeloma patients who are not [...]
Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management
22/03/2019 - 12:00
Semnur’s SP102, addressing multi-billion dollar unmet market needs, in Pivotal Phase 3 Trial with Fast Track Status from the FDA With non-opioid ZTlido, RTX, and SP102 commercial and near-commercial product lines, [...]
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
22/03/2019 - 12:25
SINGAPORE, March 22, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets, today reported [...]
Aptinyx to Present Preclinical Data on NYX-458 at the AD/PD 14th International Conference on Alzheimer’s & Parkinson’s Diseases
22/03/2019 - 12:27
EVANSTON, Ill., March 22, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, [...]
Tauriga Sciences Inc. Now Shipping its CBD Infused Chewing Gum from its Fulfillment Facility!
22/03/2019 - 13:00
New York, NY, March 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG ) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, [...]
IBEX Reports Results for the Second Quarter and the Six Months Ended January 31, 2019
22/03/2019 - 13:00
MONTREAL, March 22, 2019 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the six months ended January 31, 2019. “We were pleased with our [...]
Sun BioPharma Provides Business Update and Files Annual Report for 2018
22/03/2019 - 13:15
Front-Line Combination Study with Gemcitabine and Nab-Paclitaxel enrolling second Cohort of Phase 1a Company reinstates founder and Executive Chairman, Dr. Michael Cullen as President and Chief Executive Officer, [...]
Daxor Corporation to Exhibit at the Society of Hospital Medicine (SHM) Annual Conference 2019
22/03/2019 - 13:30
NEW YORK , March 22, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR) an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement today [...]
Wildflower Brands Featured in CannabisNewsWire Publication Discussing the Farm Bill’s Positive Effect on CBD Sales
22/03/2019 - 13:30
NEW YORK, March 22, 2019 (GLOBE NEWSWIRE) -- via CannabisNewsWire – Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) today announces its placement in an editorial published by CannabisNewsWire ("CNW"), a multifaceted [...]
SELLAS Life Sciences Reports 2018 Financial Results and Provides Business Update
22/03/2019 - 13:39
NEW YORK, March 22, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer [...]
Better Choice Company Appoints Four New Board of Director Members
22/03/2019 - 14:00
NEW YORK, March 22, 2019 (GLOBE NEWSWIRE) -- Better Choice Company, Inc (OTCQB: BTTR) (OTCQB: BTTRD) (the “Company”) today announced the appointment of Lori Taylor, Damian Dalla-Longa, Jeff Davis and Michael Galego to [...]
Coherus BioSciences Announces New Employment Inducement Grants
22/03/2019 - 14:30
REDWOOD CITY, Calif., March 22, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective March 21, 2019, the compensation committee of the company’s board of directors granted [...]

COMMUNIQUÉS West-GlobeNewswire

Pages